The underlying philosophy of the Core remains a belief that validation of diagnosis is critical to clinical research into neurodegenerative diseases and that tissue-based studies are a critical complement to in vitro studies of the biologic process that underlying these diseases. By providing these two pillars to the clinical and scientific community, the Neuropathology Core is able to make a contribution to the amelioration of suffering associated with AD and related disorders.
The Specific Aims of the Neuropathology Coreare: 1. To establish an accurate neuropathological diagnosis on all brains submitted with standardized reporting, including clinicopathological correlation and interpretation of findings, to the Clinical Core, other treating physicians andfamilies; 2. To maintain a source of brain tissue and other samples for investigators studying AD and related disorders, through preparation of tissue in a standardized manner, including determination of RNAquality, with special consideration of investigators within the Massachusetts ADRC; 3. To work with the Clinical Core to develop, store and distribute DNA, cell lines, plasma and serum collected under the Clinical Core's Biomarkers Initiative; 4. To train diagnostic and experimental neuropathologists in the neuropathology of dementing disorders; and 5. To participate in cooperative ventures with other groups studying neurodegenerative diseases, both human and animal models, including other Alzheimer Centers (ADRCs &ADCs), NACC, NINDS- supported Udall Center, as well as other consortia and individual investigators. These broad goals, which are in continuity with the historical activities of the Neuropathology Core, will enhance the value of the collected brain tissue to individual investigators whose specific research projects depend upon receiving carefully prepared and examined tissue.

Public Health Relevance

Brain tissue is a critical resource for many important experiments that are defining the underlying pathology of Alzheimer disease and other neurodegenerative diseases. The ability to use the collect tissue in experiments is essential as new therapies and disease markers are developed.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Mattos, Meghan K; Snitz, Beth E; Lingler, Jennifer H et al. (2017) Older Rural- and Urban-Dwelling Appalachian Adults With Mild Cognitive Impairment. J Rural Health 33:208-216
Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148
Wachinger, Christian; Reuter, Martin; Klein, Tassilo (2017) DeepNAT: Deep convolutional neural network for segmenting neuroanatomy. Neuroimage :
Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528
Marquié, Marta; Verwer, Eline E; Meltzer, Avery C et al. (2017) Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 5:75
Wang, Zemin; Jackson, Rosemary J; Hong, Wei et al. (2017) Human Brain-Derived A? Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. J Neurosci 37:11947-11966
Liu, Ganqiang; Locascio, Joseph J; Corvol, Jean-Christophe et al. (2017) Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol 16:620-629
Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189
Xia, Chenjie; Makaretz, Sara J; Caso, Christina et al. (2017) Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol 74:427-436
Dickerson, Bradford C; McGinnis, Scott M; Xia, Chenjie et al. (2017) Approach to atypical Alzheimer's disease and case studies of the major subtypes. CNS Spectr 22:439-449

Showing the most recent 10 out of 858 publications